<DOC>
	<DOCNO>NCT02234440</DOCNO>
	<brief_summary>In study , consecutive patient cryptogenic cirrhosis ( NASH-related cirrhosis ) , come ILBS ( Institute Liver &amp; Biliary Sciences ) OPD ( Out patient Department ) get admit ward enrol fulfillment inclusion/exclusion criterion consent patient . These patient randomise either metformin arm conventional treatment arm . After enrollment subject monitor every three monthly total 12 month till primary endpoint achieve . At end study , outcome measure appropriately .</brief_summary>
	<brief_title>Effect Metformin Disease Progression Patients With Cryptogenic Cirrhosis ( NASH-related Cirrhosis ) With Diabetes Impaired Glucose Tolerance Insulin Resistance</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Age 18 year 2 . Patients cryptogenic cirrhosis { NASH ( Nash Alcoholic Steatohepatitis ) relate cirrhosis } 3 . Presence diabetes mellitus insulin resistance 1 . Patients heart failure 2 . Patients acute kidney injury time enrollment 3 . Patients CKD ( Chronic Kidney Disease ) S. Creatinine &gt; 1 mg/dL 4 . Patient active upper GI bleeding settle 5 . Patient SIRS/sepsis/shock 6 . Patient ICU ( Intensive Care Unit ) 7 . Pregnancy 8 . Patients hepatocellular carcinoma 9 . Patients willing participate study 10 . Patients form decompensation time enrollment study 11 . Patient large esophageal varices/ patient beta blocker patient HVPG ( Hepatic Venous Pressure Gradient ) non responder betablocker 12 . Patient already receive Metformin prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>